Glancy
Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of Sanofi (the “Company”)
(NYSE:SNY) concerning possible violations of federal securities laws.
The investigation is focused on certain statements issued by Sanofi
between February 7, 2013 and December 3, 2014, concerning the
Company’s operations and financial performance.
Please contact Casey
Sadler at (310) 201-9150, or at shareholders@glancylaw.com
to discuss this matter. If you inquire by email, please include your
mailing address, telephone number and number of shares purchased.
Sanofi discovers, develops and distributes therapeutic solutions,
including pharmaceuticals and vaccines used by veterinarians, consumer
health care products, and generic medicines. The investigation is
related to allegations that Sanofi misrepresented or failed to disclose
that the Company was making improper payments to healthcare
professionals in connection with the sale of pharmaceutical products, in
violation of federal law, and that Sanofi’s internal controls over
financial reporting were inadequate.
If you purchased Sanofi shares between February 7, 2013 and December 3,
2014, if you have information or would like to learn more about these
claims, or have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact Casey
Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park
East, Suite 2100, Los Angeles, California 90067 at (310) 201-9150, Toll
Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2014